Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Randomized, Placebo-controlled, Double-blind Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AGMB-129 in Patients With Fibrostenotic Crohn's Disease

NCT05843578 is registered in ClinicalTrials.gov with Agomab Spain S.L.U. as lead sponsor.

NCT NCT05843578
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05843578 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Randomized, Placebo-controlled, Double-blind Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AGMB-129 in Patients With Fibrostenotic Crohn's Disease
Lead sponsor
Agomab Spain S.L.U.
Phase
Phase 2
Overall status
Completed
Start date
August 1, 2023
Completion date
June 20, 2026
Enrollment
103 (actual)
Sites
52

Conditions

As the registry lists them; a condition with its own page is linked.

fibrostenotic crohn's disease